Sutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeting ADC (GlobeNewswire) - Jan 4, 2024 - "Luvelta FolRα-targeting ADC Franchise Upcoming Milestones: (i) The registration-directed trial, REFRαME-O1, in PROC is enrolling, with 26 active sites across 5 countries and an anticipated ~140 sites in ~20 countries by the end of 2024. Part 1 of the trial is expected to be completed in the first half of 2024; (ii) Initiation of REFRαME-P1, a registration-enabling trial for pediatric patients with CBF/GLIS AML, is planned for the first half of 2024; (iii) An Investigational New Drug (IND) application submission is planned in non-small cell lung cancer (NSCLC) in the first half of 2024."
IND • New trial • Trial status • Acute Myelogenous Leukemia • Non Small Cell Lung Cancer • Ovarian Cancer
|